Ovarian Cancer | Disease Landscape & Forecast | G7 | 2022

The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.), Rubraca (Clovis Oncology), and Zejula (GlaxoSmithKline). We anticipate that the angiogenesis and PARP inhibitor stronghold will continue throughout the forecast period, principally as part of combination regimens with immune checkpoint inhibitors. The late-phase pipeline for ovarian cancer has expanded in recent years and spans a variety of drug classes. Several novel therapies are set to enter the ovarian cancer market and diversify treatment options.

Questions answered

  • What is the size of clinically and commercially relevant drug-treatable ovarian cancer populations, and how will drug-treatment rates change over time?
  • What is the current state of treatment for ovarian cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer therapy market?
  • What are the main drivers of and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report